Bhavana Pothuri, MD, and Krishnansu S. Tewari, MD, discussed the treatment options of a patient with advanced endometrial cancer and participants chose an immune checkpoint inhibitor to use for therapy.
In separate virtual live events, Bhavana Pothuri, MD, and Krishnansu S. Tewari, MD, discussed the treatment options of a patient with advanced endometrial cancer and participants chose an immune checkpoint inhibitor to use for therapy.
CASE SUMMARY
In August 2021, a 64-year-old postmenopausal woman presented to her gynecologist with abnormal uterine bleeding lasting 4 months. She underwent menopause at 55 years of age. She is a widow, has no children, and lives alone. She has a medical history of gravida 1, para 0; arthritis; obesity (body mass index = 40); and hypertension well controlled with once-daily angiotensin-converting enzyme inhibition. Her 2020 Papanicolaou test was negative, and ECOG performance status was 1.
She was counseled on surgical options, then scheduled accordingly. She had stage IA, grade 1 endometrial cancer. Immunohistochemistry/molecular testing results showed a mismatch repair deficiency and microsatellite instability–high status, and 3+ estrogen receptor–positive disease.
In August 2022, she reported intermittent pelvic pain over prior 4 weeks. CT scan of the chest, abdomen, and pelvis (CAP) suggested relapsed/metastatic disease with involvement of 1 right external iliac lymph node. Carboplatin/paclitaxel (6 cycles every 4 weeks) was administered, chemotherapy was well tolerated, and a complete response was recorded at end of regimen.
In April 2023, disease relapse was documented on routine follow-up. CT CAP scan showed heterogeneously enhancing mass in right suprarenal space, multiple bilateral pulmonary nodules, and a new right internal iliac lymph node (in addition to the previously observed positive lymph node).
Fine-needle aspiration of the suprarenal mass confirmed metastatic endometrioid adenocarcinoma. The patient was counseled about systemic therapy options, during which she repeatedly expressed concerns about adverse events. Through shared decision-making, immune checkpoint inhibitor monotherapy was planned.
REFERENCE
1. NCCN. Clinical Practice Guidelines in Oncology. Uterine neoplasms, version 1.2024. Accessed February 2, 2024. http://tinyurl.com/28y356bt
Care Teams Ease Inpatient/Outpatient Transitions in Multiple Myeloma
December 5th 2024Patients with multiple myeloma face a complex, decades-long treatment journey involving care coordination, insurance challenges, and multiple providers, highlighting the need for comprehensive care plans to ensure optimal outcomes.
Read More
Fellow's Perspective: Patient Case of Newly Diagnosed Multiple Myeloma
November 13th 2024In a discussion with Peers & Perspectives in Oncology, fellowship program director Marc J. Braunstein, MD, PhD, FACP, and hematology/oncology fellow Olivia Main, MD, talk about their choices for a patient with transplant-eligible multiple myeloma and the data behind their decisions.
Read More